Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer

Jeon, Yoon Kyung; Sung, Sook-Whan; Chung, Jin-Haeng; Park, Weon Seo; Seo, Jeong‐Wook; Kim, Chul Woo; Chung, Doo Hyun

doi:10.1016/j.lungcan.2006.08.015

Cited by 80 publications

(64 citation statements)

References 37 publications

(86 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since there might be a potential regional disparity in NSCLC patients with RET fusions like the variance in EGFR mutations, subgroup analysis of demographic features was also conducted among Asians and non-Asians. 27 It was not conducted in histology type and TNM stage on account of limited data of non-Asian group.…”

Section: Discussionmentioning

confidence: 99%

The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis

Chen

Wang

Xie

et al. 2015

Cancer Biology & Therapy

View full text Add to dashboard Cite

(2015) The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis, Cancer Biology & Therapy, 16:7, 1019-1028, DOI: 10.1080/15384047.2015 Purpose. The RET fusion gene is a novel oncogene observed in a subset of NSCLC in recent years. Nevertheless, the results of epidemiological studies concerning the gene remain unclear. Thus, a meta-analysis was conducted to evaluate the correlation of RET fusion gene with demographic and clinicopathological features of NSCLC. Methods. PubMed, Embase, and Web of Science databases were searched to identify eligible studies. The association of RET fusion gene occurrence with gender, age, smoking status, histology type and tumor stage were analyzed in metaanalysis. Subgroup analysis according to patients' location (Asian and non-Asian) was also conducted. Odds ratio (OR) and 95% confidence interval (95% CI) were calculated to assess the correlation. Results. Nine studies with a total of 6,899 NSCLC patients met the inclusion criteria. A total of 84 patients with RET fusion gene were detected. The RET fusion gene was identified at significantly higher frequencies in female (OR D 0.55, 95%CI D 0.35-0.85) than male patients and in young (<60 ) patients (OR D 0.43, 95%CI D 0.19-0.99) than old patients ( 60 ), particularly in patients from Asian. A significant higher frequency was also identified in non-smokers (OR D 0.28, 95% CI D 0.16-0.49), and in patients with lung adenocarcinomas (OR D 3.59, 95%CI D 1.50-8.56). Additionally, no association between RET fusion gene and the TNM stage of tumor was observed. Conclusion. RET fusion gene occurred predominantly in Asian females with younger age, in non-smokers, and in lung adenocarcinomas patients. This subset of NSCLC patients might be good candidates for personalized diagnostic and therapeutic approaches.

show abstract

Section: Discussionmentioning

confidence: 99%

The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis

Chen

Wang

Xie

et al. 2015

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…EGFR gene copy number was estimated using an LSI EGFR SpectrumOrange/CEP7 SpectrumGreen probe set (Abbott Molecular) and interpreted according to the University of Colorado Cancer Center system as described previously. 29 Briefly, cases with high polysomy (≥4 copies of the EGFR gene in ≥ 40% of tumor cells) or gene amplification were deemed to be EGFR FISH positive. MET gene copy number was estimated using an LSI MET SpectrumRed/CEP7 SpectrumGreen probe (Abbott Molecular) and interpreted using the above University of Colorado Cancer Center system or Cappuzzo criteria (high MET gene copy number; mean ≥ 5 copies per cell) as described previously.…”

Section: Patients and Samplesmentioning

confidence: 99%

Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status

et al. 2015

Self Cite

View full text Add to dashboard Cite

Immunotherapies targeting the programmed cell death-1/programmed cell death-ligand 1 pathway have emerged as promising therapeutic strategies for lung cancer. However, the expression pattern and prognostic implications of programmed cell death-ligand 1 and 2 and programmed cell death-1 in comparison with the histology and genetic alterations in pulmonary adenocarcinomas remains unclear and thus were addressed here. Programmed cell death-ligand 1 and 2 expression in tumor cells and the quantities of programmed cell death-1 + and CD8 + tumor-infiltrating lymphocytes were immunohistochemically evaluated in 497 resected pulmonary adenocarcinomas and analyzed according to clinicopathological and genetic statuses. Programmed cell death-ligand 1 and 2 expression were observed in 59% and 64% of pulmonary adenocarcinomas, respectively, and showed a strong positive correlation with each other (Po 0.001). Programmed cell death-ligand 1 expression was higher in nodal metastasis cases (P = 0.006), smokers (P = 0.056), poorly differentiated tumors and histologic subtypes of solid and micropapillary patterns (Po0.001). There was no significant difference in programmed cell death-ligand 1 and 2 expression according to EGFR mutation status. However, programmed cell death-ligand 1 expression was correlated with ALK translocation (P = 0.054) and expression of EGFR and MET (Po 0.001). Meanwhile, programmed cell death-ligand 2 expression was correlated with ALK translocation (P = 0.052), and expression of MET (Po 0.001) and ERBB2 (P = 0.013). The numbers of CD8 + and programmed cell death-1 + lymphocytes were higher in smokers (P = 0.012 and 0.016) and MET-expressing adenocarcinomas (Po 0.001). Patients expressing programmed cell death-ligand 1 and/or high ratios of programmed cell death-1 + /CD8 + lymphocytes showed shorter disease-free survival (P = 0.001). Our study demonstrated that programmed cell death-ligand 1 and 2 expression varied with histology, EGFR, ALK, MET, and ERBB2 statuses, and activation of the programmed cell death-1/programmed cell death-ligand 1 pathway may be a poor prognostic factor in pulmonary adenocarcinomas.

show abstract

“…Thus, these markers were not considered for the purpose of this study. Similarly, we did not consider EGFR, which has been reported to be mutated in NSCLC, because the prognostic value of EGFR overexpression in untreated NSCLC remains controversial (60,61).…”

Section: Metamentioning

confidence: 99%

Survival prediction of stage I lung adenocarcinomas by expression of 10 genes

Bianchi¹,

Nuciforo²,

Vecchi³

et al. 2007

J. Clin. Invest.

102

View full text Add to dashboard Cite

Adenocarcinoma is the predominant histological subtype of lung cancer, the leading cause of cancer deaths in the world. At stage I, the tumor is cured by surgery alone in about 60% of cases. Markers are needed to stratify patients by prognostic outcomes and may help in devising more effective therapies for poor prognosis patients. To achieve this goal, we used an integrated strategy combining meta-analysis of published lung cancer microarray data with expression profiling from an experimental model. The resulting 80-gene model was tested on an independent cohort of patients using RT-PCR, resulting in a 10-gene predictive model that exhibited a prognostic accuracy of approximately 75% in stage I lung adenocarcinoma when tested on 2 additional independent cohorts. Thus, we have identified a predictive signature of limited size that can be analyzed by RT-PCR, a technology that is easy to implement in clinical laboratories.

show abstract

Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer

Cited by 80 publications

References 37 publications

The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis

The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis

Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status

Survival prediction of stage I lung adenocarcinomas by expression of 10 genes

Contact Info

Product

Resources

About